| Brohl, Andrew |
| Active, not recruiting | 3 | 101 | US | Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution | University of Washington, EMD Serono | Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8 | 04/26 | 02/29 | | |
|
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients |
|
|
| Active, not recruiting | 2 | 17 | US | Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation | H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated | Melanoma | 06/28 | 06/28 | | |
| Recruiting | 2 | 201 | Europe, US, RoW | INBRX-109, Placebo | Inhibrx Biosciences, Inc | Conventional Chondrosarcoma | 12/24 | 06/25 | | |
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma |
|
|
| Recruiting | 2 | 26 | US | Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin | 05/25 | 05/26 | | |
| Recruiting | 2 | 25 | US | Ipilimumab, Yervoy, Axitinib, Inlyta | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Melanoma | 03/26 | 03/27 | | |
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients |
|
|
| Recruiting | 2 | 29 | US | Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc. | Melanoma Stage III, Melanoma Stage IV, Inoperable Disease | 09/24 | 09/29 | | |
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma |
|
|
| Recruiting | 2 | 37 | US | Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Uveal Melanoma, Ocular Melanoma | 07/26 | 07/26 | | |
| Active, not recruiting | 1/2 | 21 | US | Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma | 10/24 | 10/25 | | |
NCT04160065: Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers |
|
|
| Completed | 1 | 23 | US | IFx-Hu2.0, pAc/emm55 | TuHURA Biosciences, Inc., H. Lee Moffitt Cancer Center and Research Institute, University of Southern California, Dana-Farber Cancer Institute, Huntsman Cancer Institute | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers | 10/23 | 08/24 | | |
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 1 | 30 | US | Cemiplimab-Rwlc, Libtayo | H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | 06/27 | 06/27 | | |
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma |
|
|
| Recruiting | 1 | 50 | US | Encorafenib Pill, Binimetinib Pill, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation | 01/25 | 01/26 | | |
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma |
|
|
| Recruiting | 1 | 34 | US | Vismodegib 150 MG Oral Capsule, Erivedge | H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc. | Advanced Basal Cell Carcinoma | 12/28 | 12/29 | | |
| Chahoud, Jad |
NCT04126070: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors |
|
|
| Active, not recruiting | 2 | 60 | US | Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere | Xiao X. Wei, MD, Bristol-Myers Squibb | Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma | 12/24 | 06/25 | | |
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma |
|
|
| Recruiting | 2 | 25 | US | Dostarlimab, Jemperli, Niraparib, Zejula | H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline | Penile Carcinoma | 10/25 | 10/26 | | |
| Active, not recruiting | 1 | 21 | US | CG0070, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, CG Oncology, Inc., Richard M. Shulze Family Foundation | Muscle-Invasive Bladder Carcinoma, Bladder Cancer | 01/25 | 02/25 | | |
NCT05579847: Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy |
|
|
| Active, not recruiting | N/A | 20 | US | mHealth Smart Phone Application, eHEALS digital literacy test, Weekly Quiz, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Patient Post Intervention Survey | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Renal Cell Carcinoma Stage IV | 01/24 | 01/25 | | |
